Sector Spotlight: Healthcare Deserves A Close Exam For 2016

|
Includes: AET, ANTM, BBC, BBH, BBP, CURE, FBT, FHLC, FXH, HQH, HQL, IBB, IYH, LABD, LABU, LLY, MRK, PBE, PFE, RXD, RXL, RYH, SBIO, THC, THQ, UBIO, UNH, VHT, XBI, XLV, ZBIO
by: TD Ameritrade

Last year, the healthcare sector pumped out fit vital signs as one of the best-performing sectors of the 10 in the S&P 500 (SPX). Can this traditionally defensive sector, now juiced with healthy growth and momentum plays, do it again in 2016? The answer is a qualified maybe.

The Well-Being Back Story

The healthcare sector is big and diverse, and it includes industries that run the well-being gamut from managed healthcare to biotechnology, and, of course, big-name pharmaceutical companies. Each industry has its own unique flavor, and what Patrick O'Hare, chief market analyst at Briefing.com, calls the "sweet spot" for investors itching for perceived safety lined with growth opportunities. "There is growth to be found there based on demographics, but it is also regarded as a defensive play," O'Hare says. "Relatively speaking, demand for healthcare holds pretty constant no matter what type of economic cycle you have going on."

The high-flying biotech space may spark memories of the dotcom era, as it's become a magnet for growth and momentum investors. Many biotech firms are still in the story-stock stage: They do drug research and development, but have no profits or revenues. The managed healthcare industry, on the other hand, rocked in 2015 with double-digit gains. It includes names like UnitedHealth Group (NYSE:UNH), Aetna (NYSE:AET), and Anthem (NYSE:ANTM). Others within the sector include healthcare distributors - think hospital systems like Tenet Healthcare Corp. (NYSE:THC) - and healthcare equipment. The pharmaceuticals are marked with familiar names like Merck & Co. (NYSE:MRK), Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY).

Two Sides To The Thermometer

This won't be an easy year for the healthcare sector, which will face conflicting headwinds of positive long-term influences from aging demographics and rising demand, coupled with a political arena charged with disapproval of drug pricing and of the Affordable Care Act, commonly referred to as Obamacare. "Politics will enter the fray in 2016," O'Hare says. "You can already see it in the Democratic and Republican debates. You are hearing attention paid to the exorbitant pricing of drugs and the need to get that under control. And, on the Republican side, you are hearing about the repeal of Obamacare."

The political chatter will skew toward the negative for this sector throughout the year, but "I don't think it will be the undoing of the sector by any means," O'Hare adds.

On the plus side, "There will be some defensive positioning in this sector, as a lot of investors can identify it as having pretty good long-term growth demographics with the aging baby boomers, and the implementation of Obamacare brought more people into the health system," O'Hare says.

A Healthy Risk

Solid sales growth is projected in 2016 for the sector as a whole, according to S&P Capital IQ. International sales now account for more than 50% of sales for most large multinational drug and equipment companies, which leaves the sector poised to benefit from global expansion and sales efforts. And let's not forget new lines of drugs. Through November 30, the FDA approved 40 new molecular entities (NMEs), or novel new drugs. That mirrors 2014, when the highest number of NMEs were approved in nearly 20 years, according to S&P Capital IQ data.

Within the sector, biotech stocks, considered "pure growth plays," generate much investor interest from momentum traders, says O'Hare. A word of caution: without earnings, the stock prices are vulnerable to quick reversals if their drugs don't receive approval. "They have become very interesting trading vehicles," O'Hare says. "But (biotech) is for people with a higher risk tolerance and a strong stomach to play short-term moves."

He warns investors to be picky because valuations could be at risk. "I don't think the market in 2016 will be of the mindset of paying up for growth at any price," O'Hare says. "Investors will be more discerning across the landscape."

Disclaimer: TD Ameritrade, Inc., member FINRA/SIPC. TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank. Commentary provided for educational purposes only. Past performance is no guarantee of future results or investment success.

Options involve risks and are not suitable for all investors. Please read Characteristics and Risks of Standardized Options before investing.